In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Arcutis Biotherapeutics, with a price target of $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tyler Van Buren has given his Buy rating due to a combination of factors including strong sales performance and promising future growth prospects for Arcutis Biotherapeutics. The company reported total product sales that exceeded expectations by approximately 14%, driven by increased demand and improved gross-to-net adjustments. Additionally, the management’s guidance for 2026 sales is above consensus, indicating confidence in sustained growth.
Furthermore, Arcutis Biotherapeutics is well-positioned in the market with its Zoryve franchise, which is widely covered by insurance and has significant market potential. The company is expected to benefit from indication expansion and commercial dynamics, such as the recent foam launch for scalp and body psoriasis and the establishment of a national dedicated pharmacy. These initiatives, along with a robust life-cycle strategy and a promising pipeline, support the Buy rating.
In another report released today, Needham also maintained a Buy rating on the stock with a $30.00 price target.
Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARQT in relation to earlier this year.